Core Viewpoint - The company, Gilead Sciences-B (01672), has selected ASC36 as a clinical development candidate, which is expected to be a best-in-class monthly subcutaneous injection amylin receptor agonist for obesity treatment, with plans to submit an IND to the FDA by Q2 2026 [1] Group 1: Product Development - ASC36 is developed using Gilead's AI-assisted drug discovery and long-acting drug development platform technology [1] - The optimized design of ASC36 allows for a longer apparent half-life and higher bioavailability per milligram of peptide, supporting monthly subcutaneous administration with an injection volume not exceeding 1 milliliter [1] - These optimized characteristics are expected to reduce costs in large-scale production [1] Group 2: Market Reaction - Following the announcement, Gilead's stock rose over 4%, specifically by 4.62%, reaching HKD 9.74, with a trading volume of HKD 12.814 million [1]
港股异动 | 歌礼制药-B(01672)现涨超4% 皮下注射胰淀素受体激动剂ASC36进入临床开发阶段